Anlong Bio Secures Tens of Millions in Series A+ Financing to Advance AAV Gene Therapy AL-001 and Small Nucleic Acid Drug Pipeline

At the beginning of the New Year in January 2024, Anlong successfully completed a multi-million-dollar A+ round of financing.This round of financing was jointly invested by TaiKun Fund and ShunChuang Industry Investment Management Fund. The funds will be used to advance the clinical trials of Anlong's AAV gene therapy product AL-001 and the research and development of small nucleic acid innovative drugs.Since its establishment, Anlong has received investments of hundreds of millions of yuan from multiple medical capital firms. The success of this round of financing marks significant progress in Anlong's research and development, production, and clinical development of gene drugs, gaining recognition and trust from investors.

Anlong Biotech believes that gene drugs are the next wave in the biopharmaceutical field and has made extensive arrangements in this area. The company's self-developed AAV gene therapy drug, AL-001 Ophthalmic Injection, received clinical trial approval from the CDE in April 2023 and successfully completed the first dosing of a subject in July 2023. The product's indication is age-related macular degeneration (wet). This is China's first AAV gene therapy drug administered via suprachoroidal space injection (SCS), and it is also the world’s first gene therapy expressing aflibercept delivered through the suprachoroidal space. The safety of gene drugs is crucial; suprachoroidal space administration is safer and simpler compared to intravitreal and subretinal injections, causing less damage to ocular tissues. Therefore, Anlong Biotech's innovative suprachoroidal injection will be one of the core technological advantages in the gene therapy field.

Small nucleic acid drugs, due to their production being based on chemical synthesis, are the biologics closest to traditional pharmaceutical enterprises. Additionally, the specificity of small nucleic acids serves as the foundation for their safety, allowing them to be widely applied in vast chronic disease fields including hepatitis B, lipid reduction, and blood pressure control, with future potential for expansion into neurology and respiratory areas. Anlong's continuous deployment in the small nucleic acid field positions it as the most suitable partner for traditional pharmaceutical companies. Successful collaborations with listed companies Kaiyin Technology and Salubris have further matured its technology platform in the small nucleic acid space, instilling confidence to engage in more partnerships with domestic and international enterprises.

Under the current economic situation, traditional pharmaceutical companies in China and abroad, with substantial funds, are the best financing channels and partners for innovative pharmaceutical companies. Anlong will continue to actively engage in external cooperation, further solidify the establishment of its gene drug development platform, and strive to become the best partner for pharmaceutical companies both in China and internationally, contributing to the continuous development of China's biopharmaceutical industry.

Taikun Fund is a fund company under Tailong Investment. Established in 2021, Tailong Investment is a professional equity investment management institution focusing on the biopharmaceuticals, medical devices, and healthcare sectors, with a fund management scale of 20 billion RMB. Tailong Investment has a professional and experienced investment team, prioritizing investments in biopharmaceuticals, innovative medical devices, CXO core services and innovative fields, as well as outstanding biopharmaceutical industry funds. It is committed to building a science-driven, cross-cycle value investment platform for the biopharmaceutical industry.

Shunchuang Industrial Investment was established in 2023. It is a private equity and venture capital fund management company set up by Beijing Shunyi Science and Technology Innovation Group Co., Ltd. (hereinafter referred to as "Shunyi Sci-Tech"). Shunyi Sci-Tech is a state-owned enterprise established by the Shunyi District Committee and Government of Beijing Municipality to further promote the integration of high-quality assets and allocate innovative resources through market-oriented means.